Login| Sign Up| Help| Contact|

Patent Searching and Data


Matches 401 - 450 out of 121,522

Document Document Title
WO/2017/007960A1
The present disclosure provides compositions, kits, and methods of promoting neural growth and/or neural survival using IL-17c. The compositions, kits, and methods can be used to promote neural growth and/or neural survival in a variety ...  
WO/2017/007825A1
In one aspect, the disclosure provides methods for treating a neurodegenerative disorder, comprising administering to a subject in need thereof a therapeutically effective amount of a nucleic acid molecule and a therapeutically effective...  
WO/2017/006932A1
The present invention relates to a composition for treating peripheral nerve injury, which can promote normal regeneration of nerves when the nerves are injured and consequently can prevent the formation of neuroma to prevent the subsequ...  
WO/2017/005136A1
Cocktails of chemical inducers of neuron-like properties (CINP) is provided, which includes cAMP agonists, neurogenic small molecules, glycogen synthase kinase inhibitors, TGFβ receptor inhibitors, and BET family bromodomain inhibitors ...  
WO/2017/006048A1
The invention relates to compounds of formula I (I) or the salts thereof, and to the use of same in the pharmaceutical, cosmetic or agrofood industry.  
WO/2017/005711A1
The invention relates to bromodomain-protein-inhibiting, in particular BET-protein-inhibiting, and preferably BRD4-inhibiting phosphorous- and sulfur-substituted benzodiazepine derivatives of the general formula (I), in which R1, R2, R3,...  
WO/2017/007755A1
This invention provides compounds that are inhibitors of HDAC2. The compounds (e.g., compounds according to Formula (I) or any one of Compounds 100-175) accordingly are useful for treating, alleviating, or preventing a condition in a sub...  
WO/2017/007008A1
Provided are novel low-molecular-weight compounds for suppressing the inductive production of MMPs, especially MMP-9, rather than the constitutive production of MMP-2. The present invention pertains to compounds represented by formula (I...  
WO/2017/006953A1
Provided is a compound having TrkA-inhibiting activity, or a pharmaceutically acceptable salt thereof. The present invention pertains to a compound represented by formula (I) or a pharmaceutically acceptable salt thereof, and a pharmaceu...  
WO/2017/004811A1
Provided in the application are an active peptide for inhibiting an AMPA receptor and a preparation method and the use thereof. The preparation method for the active peptide comprises the following steps: 1) salmon skin is soaked and the...  
WO/2017/006290A1
The present application relates to a modified release composition comprising nicergoline, or its pharmaceutically acceptable salt thereof, at least one rate-controlling polymer and one or more other pharmaceutically acceptable excipients...  
WO/2017/006407A1
A nerve cell death inhibitor, an anti-Alzheimer's disease agent, a brain hypofunction inhibitor and a drug or food having an anti-Alzheimer's disease effect or a brain hypofunction-inhibiting effect, each containing as an active ingredie...  
WO/2017/003466A1
The subject invention concerns materials and methods for conversion of non- neuronal cells into neurons. The subject invention also concerns methods for screening drugs and other compounds for activity in treating Alzheimer's disease usi...  
WO/2017/000276A1
The present invention is directed to dihydropyrazolopyrimidinone compounds of formulas (I) and (II) which are useful as therapeutic agents for the treatment of central nervous system disorders associated with phosphodiesterase 2 (PDE2). ...  
WO/2017/001570A3
Polynucleotides encoding peptides, proteins, enzymes, and functional fragments thereof are disclosed. The polynucleotides of the disclosure can be effectively delivered to an organ, such as the lung, and expressed within cells of the org...  
WO/2017/000869A1
The present invention falls within the technical field of medicines. In particular, the present invention relates to a thiazideamide derivative compound, a pharmaceutically acceptable salt or solvate thereof, a pharmaceutical composition...  
WO/2017/004385A1
A method for detecting circulating levels of beta amyloid peptides in an individual by administration of one or more inhibitors of an extracellular proteolytic pathway in blood and detection of the beta amyloid peptides in the blood or a...  
WO/2017/004405A1
Disclosed are new small molecules having a substituted quinazoline core structure and the uses thereof for modulating glucocerebrosidase activity. Also disclosed are pharmaceutical compositions comprising the small molecules or activated...  
WO/2017/003935A1
TThe present invention is directed to a transdermal delivery device comprising ketamine and formulations thereof. The present invention is also directed to a transdermal delivery device comprising ketamine for the treatment of major depr...  
WO/2017/002829A1
[Problem] To prevent abuse of a pharmacologically active ingredient by an abuser by providing a pharmaceutical composition having an abuse-prevention function (abuse by nasal inhalation, abuse by injection, and abuse by extracting a drug...  
WO/2017/000270A1
The present invention relates to a crystal form A and a crystal form B of sertraline citrate, and preparation methods therefor. The crystal form A and the crystal form B of sertraline citrate have good dissolvability, high dissolution an...  
WO/2017/000277A1
The present invention is directed to substituted triazolo bicycliccompounds of formula (I) which are useful as therapeutic agents for the treatment of central nervous system disorders associated with phosphodiesterase 2 (PDE2). The prese...  
WO/2017/001568A1
The invention relates to the use of interleukin 4 for preventing and treating amyotrophic lateral sclerosis. In particular, the invention relates to the use of an interleukin 4 polypeptide, a nucleic acid encoding said polypeptide or a c...  
WO/2017/004408A1
Disclosed are new small molecules having a 4-methylpyrrrolo[l,2-a]pyrimidine- 8-carboxamide core structure and the uses thereof for modulating glucocerebrosidase activity. Also disclosed are pharmaceutical compositions comprising the sma...  
WO/2017/004226A1
The present disclosure relates to the use of inositol-stabilized arginine ("ASI") for improving cognition. For example, in some implementations, methods include administering an amount of ASI effective to improve cognition in humans. Som...  
WO/2017/003995A1
The present invention relates to compounds of Formula I and pharmaceutically acceptable compositions thereof, useful as TBK/IKKε inhibitors.  
WO/2017/002865A1
Provided is a core-shell structure having high cutaneous permeability. This core-shell structure is provided with a core part containing a hydrophilic drug having a molecular weight of 400 or higher, and a shell part containing a surfact...  
WO/2017/001812A1
This invention provides compounds of formula (I) and salts thereof, which have activity as inhibitors of N-myristoyl transferase (NMT). The invention also relates to uses of such compounds as medicaments, in particular in the treatment o...  
WO/2017/003469A1
The subject invention concerns materials and methods for treating depression, stress disorders, such as PTSD, anxiety disorders, and/or a neurodegenerative disease or condition in a person or animal. In one embodiment, a person or animal...  
WO/2016/208696A1
Disclosed is a fusion protein comprising brain-derived neurotrophic factor (BDNF). The fusion protein is a fusion protein of BDNF and anti-human transferrin receptor antibody within a specific range, and enables BDNF administered into bl...  
WO/2016/208602A1
[Problem] The purpose of the present invention is to provide a novel pyrazole derivative, or a pharmaceutically acceptable salt thereof, and a pharmaceutical composition containing same and a pharmaceutical use thereof. [Solution] The pr...  
WO/2016/210180A3
Methods are provided herein for treating mania in mood disorders and other neurological diseases or disorders. The methods provided herein comprise administering a VMAT2 inhibitor to a subject in need thereof. A VMAT2 inhibitor useful in...  
WO/2016/207794A1
The invention provides methods for enhancing neurogenesis in an animal. In one embodiment, a method for enhancing neurogenesis in an animal can comprise identifying an animal that is suffering from cognitive decline, that is at risk of b...  
WO/2016/210123A1
Biomarkers are not as commonly used in ALS drug development as in the drug development process for oncology. Biomarkers are important component of the ALS drug development pathway to demonstrate drug effect and target engagement, in a re...  
WO/2016/206551A1
The present invention provides an application of a Src protein inhibitor comprising N-(2-chloro-6-methylphenyl)-2-{6-[4-(3-hydroxyethyl)-1-piper azinyl]-2-methyl-4-pyrimidinylamino}-5-thiazole methanamide(formula I) in a drug for the pre...  
WO/2016/210120A1
The invention relates to the treatment of neurodegenerative disorders with ceramidase inhibitor.  
WO/2016/210372A3
Disclosed is a method of treating a subject who has a neurological disease. The neurological disease may be associated with altered C9ORF72 protein activity. In one aspect, the method includes a step of administering an effective dose of...  
WO/2016/207413A1
The present invention refers to the use of protein kinase inhibitors and more specifically to the use of inhibitors of the protein kinase c-Jun N-terminal kinase, JNK inhibitor sequences, chimeric peptides, or of nucleic acids encoding s...  
WO/2016/208775A1
The present invention provides a compound having a cholinergic muscarinic M1 receptor positive allosteric modulator activity, which may be useful as a prophylactic or therapeutic drug for Alzheimer's disease, schizophrenia, pain, sleep d...  
WO/2016/206699A1
Title: Iron carbohydrate complex for treatment of fetal metal defi- ciency Disclosed herein is a pharmaceutical composition comprising an iron carbohydrate complex for use in a method for treatment or prevention of an iron deficiency of ...  
WO/2016/208695A1
Disclosed is a means that can be used for modifying a biologically or pharmacologically active substance from a form incapable of permeating the blood-brain barrier to a form capable of permeating the blood-brain barrier. Also disclosed ...  
WO/2016/208045A1
The present invention addresses the problem of providing a medicinal composition for treating ataxia associated with spinocerebellar degeneration, said medicinal composition reducing a risk of side effects caused by an increase in parath...  
WO/2016/208556A1
The present application provides a relaxing composition including precious metal microparticles and a method for relaxing a subject by the composition.  
WO/2016/206172A1
Provided is a use of MicroRNA-7 in preparation of drugs for suppressing gliosis of a nervous system. Overexpressing the MicroRNA-7 in a rat retina Muller cell line can reduce GMFB expression and inhibit generation of inflammatory factors...  
WO/2016/209765A1
A pharmaceutical composition containing a benzhydrylsulfinylacetamide antidepressant, and either or both of an SSRI uptake inhibitor and/or a stimulating antidepressant has been shown to be effective in ameliorating symptoms of dementia,...  
WO/2016/210144A1
Described are compositions of matter and protocols useful for treatment of neurological and other disorders associated with inflammatory activities. In some embodiments the invention provides means of modulating neuroinflammation through...  
WO/2016/210180A2
Methods are provided herein for treating mania in mood disorders and other neurological diseases or disorders. The methods provided herein comprise administering a VMAT2 inhibitor to a subject in need thereof. A VMAT2 inhibitor useful in...  
WO/2016/206573A1
The invention provides compounds that inhibit FTO (fat mass and obesity), including pharmaceutically acceptable salts, hydrides and stereoisomers thereof. The compounds are employed in pharmaceutical compositions, and methods of making a...  
WO/2016/203347A1
The present invention is directed to compounds of Formula I: or a pharmaceutically acceptable salt thereof, wherein the substituents A, R1, R2, R3a, R3b, R4a, R4b and n are as defined herein. The inventions also directed to pharmaceutica...  
WO/2016/203404A1
The present invention relates to compounds of formula I. The compounds are inhibitors of the Src Homolgy-2 phosphatase (SHP2) and thus useful in the treatment of Noonan Syndrome, Leopard Syndrome and cancer.  

Matches 401 - 450 out of 121,522